199 related articles for article (PubMed ID: 24712723)
1. Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Maucieri A; Gerardi MA; Vischioni B; Cambria R; Garibaldi C; Cattani F; Vavassori A; Matei DV; Musi G; De Cobelli O; Orecchia R
BJU Int; 2014 Dec; 114(6b):E3-E10. PubMed ID: 24712723
[TBL] [Abstract][Full Text] [Related]
2. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
[TBL] [Abstract][Full Text] [Related]
3. Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO Trial.
Wortel RC; Pos FJ; Heemsbergen WD; Incrocci L
J Sex Med; 2016 Nov; 13(11):1695-1703. PubMed ID: 27665195
[TBL] [Abstract][Full Text] [Related]
4. Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).
Ficarra V; Borghesi M; Suardi N; De Naeyer G; Novara G; Schatteman P; De Groote R; Carpentier P; Mottrie A
BJU Int; 2013 Aug; 112(3):338-45. PubMed ID: 23470027
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification.
Ficarra V; Sooriakumaran P; Novara G; Schatloff O; Briganti A; Van der Poel H; Montorsi F; Patel V; Tewari A; Mottrie A
Eur Urol; 2012 Mar; 61(3):541-8. PubMed ID: 22153926
[TBL] [Abstract][Full Text] [Related]
6. Early biochemical recurrence, urinary continence and potency outcomes following robot-assisted radical prostatectomy.
Berg KD; Thomsen FB; Hvarness H; Christensen IJ; Iversen P
Scand J Urol; 2014 Aug; 48(4):356-66. PubMed ID: 24579803
[TBL] [Abstract][Full Text] [Related]
7. Erectile function after prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
[TBL] [Abstract][Full Text] [Related]
8. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: trifecta rate of achieving continence, potency and cancer control.
Xylinas E; Durand X; Ploussard G; Campeggi A; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
Urol Oncol; 2013 Jan; 31(1):99-103. PubMed ID: 21719321
[TBL] [Abstract][Full Text] [Related]
10. Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes.
Schiavina R; Borghesi M; Dababneh H; Pultrone CV; Chessa F; Concetti S; Gentile G; Vagnoni V; Romagnoli D; Della Mora L; Rizzi S; Martorana G; Brunocilla E
Eur J Surg Oncol; 2014 Dec; 40(12):1716-23. PubMed ID: 25085795
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Cambria R; Garibaldi C; Tagaste B; Vavassori A; Cattani F; Alterio D; Gherardi F; Serafini F; Rocco B; Musi G; De Cobelli O; Orecchia R
Urol Oncol; 2011; 29(5):523-32. PubMed ID: 20005749
[TBL] [Abstract][Full Text] [Related]
12. Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy.
Pierorazio PM; Spencer BA; McCann TR; McKiernan JM; Benson MC
Urology; 2007 Oct; 70(4):717-22. PubMed ID: 17991543
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
14. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
15. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
16. Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study.
Baco E; Gelet A; Crouzet S; Rud E; Rouvière O; Tonoli-Catez H; Berge V; Chapelon JY; Eggesbø HB
BJU Int; 2014 Oct; 114(4):532-40. PubMed ID: 24930692
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.
Yap T; Ahmed HU; Hindley RG; Guillaumier S; McCartan N; Dickinson L; Emberton M; Minhas S
Eur Urol; 2016 May; 69(5):844-51. PubMed ID: 26525837
[TBL] [Abstract][Full Text] [Related]
18. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
19. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
20. Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function.
Girelli G; Franco P; Sciacero P; Cante D; Borca VC; Pasquino M; Annoscia S; Tofani S; La Porta MR; Ricardi U
Anticancer Res; 2015 Jul; 35(7):4177-82. PubMed ID: 26124375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
